199 related articles for article (PubMed ID: 29857868)
1. PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population.
Cuocolo R; Stanzione A; Rusconi G; Petretta M; Ponsiglione A; Fusco F; Longo N; Persico F; Cocozza S; Brunetti A; Imbriaco M
Eur J Radiol; 2018 Jul; 104():64-70. PubMed ID: 29857868
[TBL] [Abstract][Full Text] [Related]
2. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.
Di Campli E; Delli Pizzi A; Seccia B; Cianci R; d'Annibale M; Colasante A; Cinalli S; Castellan P; Navarra R; Iantorno R; Gabrielli D; Buffone A; Caulo M; Basilico R
Eur J Radiol; 2018 Apr; 101():17-23. PubMed ID: 29571792
[TBL] [Abstract][Full Text] [Related]
4. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
5. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
6. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
8. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
9. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
Westphalen AC; Fazel F; Nguyen H; Cabarrus M; Hanley-Knutson K; Shinohara K; Carroll PR
Int Braz J Urol; 2019; 45(4):713-723. PubMed ID: 31136112
[TBL] [Abstract][Full Text] [Related]
10. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
11. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
[TBL] [Abstract][Full Text] [Related]
12. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
Distler FA; Radtke JP; Bonekamp D; Kesch C; Schlemmer HP; Wieczorek K; Kirchner M; Pahernik S; Hohenfellner M; Hadaschik BA
J Urol; 2017 Sep; 198(3):575-582. PubMed ID: 28373135
[TBL] [Abstract][Full Text] [Related]
13. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
[TBL] [Abstract][Full Text] [Related]
15. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
Schimmöller L; Quentin M; Arsov C; Hiester A; Buchbender C; Rabenalt R; Albers P; Antoch G; Blondin D
Eur Radiol; 2014 Oct; 24(10):2582-9. PubMed ID: 24972954
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
Rais-Bahrami S; Siddiqui MM; Vourganti S; Turkbey B; Rastinehad AR; Stamatakis L; Truong H; Walton-Diaz A; Hoang AN; Nix JW; Merino MJ; Wood BJ; Simon RM; Choyke PL; Pinto PA
BJU Int; 2015 Mar; 115(3):381-8. PubMed ID: 24447678
[TBL] [Abstract][Full Text] [Related]
17. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Schouten MG; van der Leest M; Pokorny M; Hoogenboom M; Barentsz JO; Thompson LC; Fütterer JJ
Eur Urol; 2017 Jun; 71(6):896-903. PubMed ID: 28063613
[TBL] [Abstract][Full Text] [Related]
18. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
[TBL] [Abstract][Full Text] [Related]
19. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.
Tan N; Lin WC; Khoshnoodi P; Asvadi NH; Yoshida J; Margolis DJ; Lu DS; Wu H; Sung KH; Lu DY; Huang J; Raman SS
Radiology; 2017 Apr; 283(1):130-139. PubMed ID: 27861110
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.
MacAskill F; Lee SM; Eldred-Evans D; Wulaningsih W; Popert R; Wolfe K; Van Hemelrijck M; Rottenberg G; Liyanage SH; Acher P
Int Urol Nephrol; 2017 Aug; 49(8):1335-1342. PubMed ID: 28477301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
